Toronto Firm Aims for Nod for VMS System

Toronto Firm Aims for Nod for VMS System

By: Tomas Ronolski - News

Wednesday, June 5, 2019

New innovations in the health-care system: Toronto-based Ventripoint Diagnostics Ltd. (TSX-Venture:VPT) got hearts beating faster Wednesday morning, with word it has submitted for regulatory approvals in Canada and other countries for its next-generation VMS+ 3.0 system.

VMS+ 3.0 system is designed to use Artificial Intelligence for volumetric measurements and ejection fractions for all four chambers of the heart, which are key indicators in cardiac diseases.

VPT claims this system to be a cost-effective diagnostic tool for measuring whole heart function utilizing standard 2D ultrasound. The system has a new patent-pending position sensor technology developed at Ventripoint to improve patient management and overall experience during the cardiac echo exam for pediatric and adult patients

Said CEO George Adams, "I am proud of the exemplary work performed by the regulatory affairs and design and development teams as we embark on this major milestone of submitting for regulatory approvals to the FDA, Health Canada and CE Notified Body for our VMS+ 3.0 system.”

Shares of VPT grabbed a penny, or 7.1%, to 15 cents, on 270,000 shares.

Copyright © 2019 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

The Bulls Look Ready To Pounce On This Beaten Up Name
Technicals Appear To Point To New Uptrend For Clean Energy Stock
Amex through Roof on Quebec Gold Find
Melkior Price Take Flight on New Surface Grab Near Timmins

Back to Top